KEY POINTS
- This systematic review evaluated dose escalation added to short-course radiotherapy for rectal adenocarcinoma, following a PRISMA-based search of PubMed, Cochrane, and Embase through June 9, 2026. Of 884 identified records, 11 studies involving 705 patients met the inclusion criteria, with 601 patients (85.2%) receiving the prescribed boost. The studies included randomized trials, prospective single-arm studies, and retrospective cohorts, with substantial variation in disease stage, treatment intent, and additional systemic therapy.
- Most studies used standard short-course RT of 25 Gy in five fractions, followed by or combined with additional irradiation. External-beam boost doses ranged from 4–20 Gy, delivered using simultaneous integrated boost or sequential approaches. Other strategies included 10–15 Gy intraoperative RT, 10–20 Gy HDR brachytherapy, and 30–120 Gy contact X-ray brachytherapy. One included study used an alternative short-course regimen of 29 Gy in ten twice-daily fractions.
- Pathological complete response varied widely across studies and treatment pathways. Among studies using short-course RT with an additional boost and neoadjuvant chemotherapy, reported pCR rates ranged from 0% to 28%. Studies without additional neoadjuvant chemotherapy reported pCR rates of 9.6% and 41.4%, although the latter cohort predominantly included early-stage tumors. These results cannot be directly compared with standard short-course RT because tumor stage, chemotherapy, boost location, and interval to surgery differed substantially.
- Clinical complete response rates were especially variable in organ-preservation studies. Among five studies reporting cCR, rates ranged from 9.5% to 70.2%. Two studies incorporating brachytherapy boosts reported initial cCR rates of 70.2% and 34.4%, decreasing to sustained cCR rates of 53.1% and 31.3%, respectively. The apparent advantage of brachytherapy approaches was confounded by patient selection, including a greater proportion of early-stage rectal cancers, and does not establish superiority over external-beam boost techniques.
- Severe acute toxicity was highly heterogeneous and reached concerning levels in selected regimens. Reported grade ≥3 acute toxicity ranged from 0% to 62.5%, depending on the study and whether overall or gastrointestinal toxicity was assessed. Five studies reported rates exceeding 27%. In the highest-toxicity series, 10/16 patients receiving a boost of up to 20 Gy in four fractions developed grade 3 proctitis. Differences in chemotherapy, treatment intensity, dose escalation, and toxicity reporting prevent isolating the independent contribution of the boost.
- Late toxicity and postoperative complications also varied substantially. Reported grade 3 late toxicity ranged from 3.4% to 40%, while grade 4 late events ranged from 1.7% to 6.8% in studies reporting these outcomes. Excluding intraoperative RT cohorts, grade ≥3 late toxicity was generally ≤10.2%. Postoperative complication rates ranged from 7% to 50%, with five surgery-related deaths among 354 operated patients (approximately 1.4%). These events cannot be reliably attributed to radiation dose escalation because surgical procedures, patient risk, and concomitant treatments differed.
- No pooled treatment effect could be established. The authors did not perform a meta-analysis because of major clinical and methodological heterogeneity. Several studies included mixed early-stage and locally advanced disease, others boosted lymph nodes rather than the primary tumor, and some did not clearly separate pCR from cCR. The review protocol was not registered, and much of the available evidence came from small nonrandomized cohorts. Consequently, there is insufficient evidence that short-course RT dose escalation independently improves complete response, organ preservation, or survival compared with contemporary standard treatment.
CLINICAL TAKEAWAY
Adding a radiation boost to short-course rectal RT is feasible in selected patients and has produced encouraging complete response rates, particularly in some organ-preservation programs. However, the evidence is heterogeneous, severe acute toxicity can be substantial, and the independent benefit of dose escalation remains uncertain. Prospective randomized studies incorporating contemporary total neoadjuvant therapy and standardized toxicity assessment are needed before defining a preferred boost regimen.